Brief: Kancera Reports Promising Preclinical Results From Studies Of Its Fractalkine Axis Blocking Drug Candidates

Novakand Pharma AB

20/10/2022 07:35

Oct 20 (Reuters) - Kancera AB  KANC.ST :
    * KANCERA REPORTS PROMISING PRECLINICAL RESULTS FROM STUDIES
OF
ITS FRACTALKINE AXIS BLOCKING DRUG CANDIDATES IN B-CELL LYMPHOMA
    * IS HEREBY REPORTING PROMISING RESULTS SHOWING THAT ITS
FRACTALKINE AXIS BLOCKING CANDIDATE DRUGS KAND567 AND KAND145
    * WILL NOW ENGAGE WITH KEY OPINION LEADERS IN FIELD TO
REVIEW
THESE PROMISING STUDY RESULTS AND DETERMINE A POSSIBLE LINE OF
TREATMENT POSITIONING OF ITS FRACTALKINE AXIS BLOCKERS IN B-CELL
LYMPHOMA

Source text for Eikon:  ID:nMFN7D1ZfV 
Further company coverage:  KANC.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))